Home | Welcome to Contract Pharma   
Last Updated Sunday, September 14 2014
Print RSS Feed

Orexo, AZ in Respiratory Research Pact



Published January 25, 2013
Related Searches: Preclinical Development
Orexo AB has entered into an agreement with AstraZeneca for its OX-CLI preclinical program for the potential treatment of respiratory diseases. AZ has been granted rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AZ also has an option to acquire the compounds, subject to a full asset transfer agreement, under which Orexo will receive development milestones and royalties on future revenues. Financial terms were not disclosed.
 
“Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients. AstraZeneca, a leading global company within the inflammatory and respiratory area, is the optimal partner for OX-CLI and we look forward to see the project advancing,” said chief executive officer Anders Lundström.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On